艾瑞布林药物审评
Eribulin drug review.
作者信息
Shetty Nishitha, Gupta Sudeep
机构信息
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
出版信息
South Asian J Cancer. 2014 Jan;3(1):57-9. doi: 10.4103/2278-330X.126527.
Abstract
Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage. In patients with metastatic breast cancer refractory to anthracyclines and taxanes, eribulin is one of the life-saving options. Neutropenia, neuropathy and QT prolongation are the most frequent adverse events associated with this drug. Phase I/II trials are also underway in refractory lung, ovarian, pancreatic, bladder, and soft tissue tumors. Larger prospective studies will define the role of this drug in a wide variety of tumors, and the future looks very promising.
摘要
艾瑞布林是一种被批准用于治疗转移性乳腺癌的抗癌药物。这种药物是日本海洋海绵冈村软海绵的合成衍生物。它通过干扰微管生长起作用，最终在长时间的有丝分裂阻滞后导致细胞凋亡。在对蒽环类药物和紫杉烷类药物难治的转移性乳腺癌患者中，艾瑞布林是挽救生命的选择之一。中性粒细胞减少、神经病变和QT间期延长是与该药物相关的最常见不良事件。I/II期试验也正在难治性肺癌、卵巢癌、胰腺癌、膀胱癌和软组织肿瘤中进行。更大规模的前瞻性研究将确定这种药物在多种肿瘤中的作用，前景十分广阔。
相似文献
1
Eribulin drug review.艾瑞布林药物审评
South Asian J Cancer. 2014 Jan;3(1):57-9. doi: 10.4103/2278-330X.126527.
2
Potential clinical applications of halichondrins in breast cancer and other neoplasms.卤虫内酯在乳腺癌和其他肿瘤中的潜在临床应用。
Breast Cancer (Dove Med Press). 2012 Feb 8;4:9-19. doi: 10.2147/BCTT.S12423.
3
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.欧洲药品管理局对艾瑞布林治疗局部晚期或转移性乳腺癌患者的审查：人用药品委员会对科学评估的总结。
Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.
4
Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.甲磺酸艾瑞布林：一种新型海鞘素 B 类似物，用于治疗转移性乳腺癌。
Am J Health Syst Pharm. 2012 May 1;69(9):745-55. doi: 10.2146/ajhp110237.
5
Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.甲磺酸艾瑞布林（E7389）：在乳腺癌、胰腺癌、头颈部癌和非小细胞肺癌中的疗效和耐受性评价。
Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25.
6
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.奥拉帕利片剂联合艾立布林在既往接受蒽环类和紫杉类化疗的晚期或转移性三阴性乳腺癌日本患者中的 I/II 期研究。
Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.
7
Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?甲磺酸艾瑞布林治疗广泛预处理转移性乳腺癌的生存获益：下一步该如何？
Adv Ther. 2011 Nov;28(11):973-85. doi: 10.1007/s12325-011-0070-9. Epub 2011 Oct 19.
8
Advances in the treatment of soft tissue sarcoma: focus on eribulin.软组织肉瘤治疗进展：聚焦于艾瑞布林
Cancer Manag Res. 2018 Feb 1;10:207-216. doi: 10.2147/CMAR.S143019. eCollection 2018.
9
Eribulin: a novel cytotoxic chemotherapy agent.艾日布林：一种新型细胞毒性化疗药物。
Ann Pharmacother. 2012 Jun;46(6):802-11. doi: 10.1345/aph.1Q636. Epub 2012 May 22.
10
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.艾瑞布林作为一线至三线治疗用于先前接受过蒽环类药物和紫杉烷治疗的晚期或转移性乳腺癌患者的疗效和安全性。
Breast. 2017 Apr;32:66-72. doi: 10.1016/j.breast.2016.12.017. Epub 2017 Jan 3.
引用本文的文献
1
Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation.海洋来源化合物苔藓抑素1的抗癌活性：临床前和临床评估
Int J Mol Sci. 2025 Aug 11;26(16):7765. doi: 10.3390/ijms26167765.
2
The Effectiveness and Adverse Events of Eribulin Monotherapy in Indonesian Metastatic Breast Cancer (MBC) Patients.艾瑞布林单药治疗印度尼西亚转移性乳腺癌（MBC）患者的疗效及不良事件
Asian Pac J Cancer Prev. 2025 May 1;26(5):1773-1780. doi: 10.31557/APJCP.2025.26.5.1773.
3
Cardio-Oncology and Breast Cancer Therapies.心脏肿瘤学与乳腺癌治疗
Curr Treat Options Oncol. 2025 May;26(5):385-397. doi: 10.1007/s11864-025-01311-x. Epub 2025 Apr 21.
4
Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer.低剂量艾瑞布林可提高自然杀伤细胞介导的膀胱癌治疗效果。
Cancers (Basel). 2024 Nov 19;16(22):3875. doi: 10.3390/cancers16223875.
5
Eribulin in breast cancer: Current insights and therapeutic perspectives.艾日布林治疗乳腺癌：当前见解与治疗前景
World J Exp Med. 2024 Jun 20;14(2):92558. doi: 10.5493/wjem.v14.i2.92558.
6
Suppressing Anaphase-Promoting Complex/Cyclosome-Cell Division Cycle 20 Activity to Enhance the Effectiveness of Anti-Cancer Drugs That Induce Multipolar Mitotic Spindles.抑制后期促进复合物/周期蛋白依赖性激酶 20 活性以增强诱导多极有丝分裂纺锤体的抗癌药物的疗效。
Int J Mol Sci. 2024 Jun 7;25(12):6329. doi: 10.3390/ijms25126329.
7
Antimicrobial and anticarcinogenic activity of bioactive peptides derived from abalone viscera (Haliotis fulgens and Haliotis corrugata).鲍鱼内脏（皱纹盘鲍和杂色鲍）来源的生物活性肽的抗菌和抗癌活性。
Sci Rep. 2023 Sep 13;13(1):15185. doi: 10.1038/s41598-023-41491-w.
8
Chemotherapeutic drugs for soft tissue sarcomas: a review.软组织肉瘤的化疗药物：综述
Front Pharmacol. 2023 Aug 11;14:1199292. doi: 10.3389/fphar.2023.1199292. eCollection 2023.
9
Marine Sponge and Octocoral-Associated Bacteria Show Versatile Secondary Metabolite Biosynthesis Potential and Antimicrobial Activities against Human Pathogens.海洋海绵和八放珊瑚相关细菌表现出多样的次生代谢产物生物合成潜力，并对人类病原体具有抗菌活性。
Mar Drugs. 2022 Dec 30;21(1):34. doi: 10.3390/md21010034.
10
Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms.艾瑞布林在血液肿瘤临床前模型中的细胞和分子效应
Cancers (Basel). 2022 Dec 10;14(24):6080. doi: 10.3390/cancers14246080.
本文引用的文献
1
Eribulin for advanced breast cancer: a drug evaluation.艾立布林治疗晚期乳腺癌：药物评价。
J Breast Cancer. 2013 Mar;16(1):12-5. doi: 10.4048/jbc.2013.16.1.12. Epub 2013 Mar 31.
2
Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.甲磺酸艾瑞布林治疗难治性转移性乳腺癌患者：在一项随机批准试验中使用“医生选择”对照臂。
Clin Cancer Res. 2012 Mar 15;18(6):1496-505. doi: 10.1158/1078-0432.CCR-11-2149. Epub 2012 Jan 26.
3
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.一项在既往接受过紫杉烷类药物治疗的晚期非小细胞肺癌患者中进行的海鞘素 B 类似物甲磺酸艾日布林（E7389）的 II 期研究：加利福尼亚癌症联合会试验。
J Thorac Oncol. 2012 Mar;7(3):574-8. doi: 10.1097/JTO.0b013e31823f43ca.
4
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.一项在日本经大量预处理的转移性乳腺癌患者中开展的艾立布林的 II 期研究。
Ann Oncol. 2012 Jun;23(6):1441-8. doi: 10.1093/annonc/mdr444. Epub 2011 Oct 11.
5
Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice.比较甲磺酸艾瑞布林、紫杉醇和伊沙匹隆在小鼠体内的诱发周围神经病变效应。
Cancer Res. 2011 Jun 1;71(11):3952-62. doi: 10.1158/0008-5472.CAN-10-4184. Epub 2011 Apr 15.
6
Eribulin -- a review of preclinical and clinical studies.艾立布林——临床前和临床研究综述。
Crit Rev Oncol Hematol. 2012 Feb;81(2):163-84. doi: 10.1016/j.critrevonc.2011.03.002. Epub 2011 Apr 14.
7
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.艾立布林单药治疗与医生选择的治疗方案用于转移性乳腺癌患者（EMBRACE）：一项开放标签、3 期随机研究。
Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2.
8
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.甲磺酸艾日布林治疗既往接受蒽环类、紫杉类和卡培他滨治疗的局部晚期或转移性乳腺癌的Ⅱ期临床研究。
J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2.
9
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.甲磺酸艾瑞布林每21天给药一次用于晚期实体瘤患者的I期研究。
Clin Cancer Res. 2009 Jun 15;15(12):4213-9. doi: 10.1158/1078-0432.CCR-09-0360. Epub 2009 Jun 9.
10
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.甲磺酸艾瑞布林（一种软海绵素B类似物）用于先前接受过蒽环类药物和紫杉烷治疗的转移性乳腺癌患者的II期研究。
J Clin Oncol. 2009 Jun 20;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618. Epub 2009 Apr 6.
Zotero 插件